CD79A and nasopharyngeal carcinoma: In another study conducted in Taiwan [39]–[40], [51], elevated VCA/IgA and neutralizing antibodies against EBV DNAse were found to be highly specific sero-markers for predicting NPC, with a 20-fold increase in NPC risk for subjects seropositive for VCA/IgA antibodies, and a 30-fold increase for those seropositive for both biomarkers.